Assessing health utilities in schizophrenia: A feasibility study

PharmacoEconomics

Volumn 17, Issue 3, 2000, Pages 273-286

  Voruganti, Lakshmi N P ^a,c   Awad, A George ^b   Oyewumi, L Kola ^a   Cortese, Leonardo ^a   Zirul, Sandra ^a   Dhawan, Ravinder ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c London Psychiatric Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; DEPRESSION; ECONOMIC EVALUATION; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE; RATING SCALE; RELIABILITY; SCHIZOPHRENIA; VALIDATION PROCESS;

EID: 0033996484     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200017030-00005     Document Type: Article

References (33)

1. 1. World Health Organization. Schizophrenia: an international follow-up study. Chichester: World Health Organisation, 1979
2. 2. Ottawa-Carleton Friends of Schizophrenics. Schizophrenic psychosis in Canada, Ottawa (ON): Ottawa-Carleton Chapter of Ontario Friends of Schizophrenia, 1991
3. 3. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522-5
4. 4. Awad AG, Voruganti LNP, Heslegrave RJ. The aims of antipsychotic medications: what are they and are they being achieved? CNS Drugs 1995; 4: 8-16
5. 5. Awad AG. Quality of life in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington, DC: American Psychiatric Press, 1995: 883-46
6. 6. Awad AG, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997; 11: 32-47
7. 7. Lehman A. The wellbeing of chronic mental patients: assessing their quality of life. Arch Gen Psychiatry 1983; 40: 369-73
8. 8. Sullivan G, Wells K, Leake B. Quality of life of seriously mentally ill persons in Mississippi. Hosp Community Psychiatry 1991; 42: 752-4
9. 9. Voruganti LNP, Heslegrave RJ, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998; 28: 165-72
10. 10. Awad AG, Voruganti LNP. Cost-utility analysis in schizophrenia. J Clin Psychiatry 1999; 60 Suppl. 3: 22-9
11. 11. Voruganti L, Cortese L, Ouyewumi L, et al. Comparative evaluation of conventional and new antipsychotic drugs with reference to their subjective tolerability, side effect profile and impact on quality of life. Schizophr Res. In press
12. 12. Drummond M, Stoddart G, Torrance G. Cost-utility analysis. In: Methods for the economic evaluation of health care programs. Oxford: Oxford Medical Publications, 1987: 112-38
13. 13. Torrance G. Utility approach to measuring health-related quality of life. J Chronic Dis 1987; 40: 593-600
14. 14. Revicki D. Relationship between health utility and psychometric health status measures. Med Care 1992; 30 Suppl.: MS274-82
15. 15. Revicki D, Luce BR. Pharmacoeconomics research applied to psychopharmacology development and evaluation: methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Psychopharmacol Bull 1995; 31: 57-65
16. 16. Hargreaves WA, Shumway M. Pharmacoeconomics of antipsycholic drug therapy. J Clin Psychiatry 1996; 57 Suppl. 9: 66-76
17. 17. Revicki D, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, care givers and psychiatrists. Int Clin Psychopharmacology 1996; 11: 101-8
18. 18. Chouinard G, Albright P. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997; 17 (4): 298-307
19. 19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
20. 20. Kay S, Opler L, Lindenmayer J. Reliability of positive and negative syndrome scale for schizophrenia. Psychiatry Res 1988; 23: 99-110
21. 21. Amador X, Strauss DH, Yale SA, et al. Assessment of insight in psychosis. Am J Psychiatry 1993: 150: 873-80
22. 22. Heinrichs D, Hanlon E, Carpenter W, et al. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-98
23. 23. Bergner M, Bobbit RA, Carter WB, et al. The sickness impact profile: development and final revision of a health status measure. Med Care 1981; 19: 787-805
24. 24. Voruganti L, Awad AG. Sickness impact profile (SIP) as a measure of patients' quality of life (QOL) in clinical trials involving antipsychotic drugs. Annual Meeting of the American College of Neuro-Psychopharmacology; 1995 Dec 4-10; Puerto Rico
25. 25. Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33: 766-71
26. 26. Gurin G, Verhoff J, Felds S. Americans view their mental health. New York (NY): Russell Sage Foundation, 1960
27. 27. Llewellyn-Thomas H, Sutherland H, Tibshirani R, et al. Describing health suites. Med Care 1984; 22: 543-52
28. 28. von Neumann J, Morgenstern O. Theory of games and economic-behaviour. 2nd ed. Princeton (NJ): Princeton University Press, 1947
29. 29. Revicki D, Brown RE, Keller M, et al. Cost-effectiveness of new antidepressants compared with tricyclic antidepressants in managed care settings. J Clin Psychiatry 1997; 58: 47-58
30. 30. Froberg D, Kane R. Methodology for measuring health state preferences: I. Measurement strategy. J Clin Epidemiol 1989; 42: 345-54
31. 31. Froberg D, Kane R. Methodology for measuring health states preferences: II. Scaling methods. J Clin Epidemiol 1989; 42: 459-71
32. 32. Froberg D, Kane R. Methodology for measuring health states preferences: III. Population and context effects. J Clin Epidemiol 1989; 42: 585-92
33. 33. Revicki D, Murray M. Assessing mental health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1994; 1: 465-76